Holen Sie sich die Stockscreener-App
18.54
0.54%
0.10
Handel nachbörslich:
18.54
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Published on: 2025-08-14 03:20:38 - beatles.ru
RBC Capital Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $41 - 富途牛牛
Published on: 2025-08-14 00:53:45 - 선데이타임즈
Evercore ISI Maintains Buy Rating on Viridian Therapeutics with $38 Price Target - AInvest
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating - TipRanks
Viridian Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Goldman Sachs Raises Price Target for Viridian Therapeutics (VRDN) to $30: Analysts' Forecasts and Ratings. - AInvest
Viridian Therapeutics Q2 Results Beat Expectations, Analysts Revise Forecasts - AInvest
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
Oppenheimer Boosts Viridian Therapeutics' Target Price to $32.00, Maintaining 'Outperform' Rating. - AInvest
Wells Fargo Lowers Viridian Therapeutics Price Target to $26, Keeps Equal Weight Rating - AInvest
Viridian: Oppenheimer raises PT to $32 from $28, maintains Outperform rating. - AInvest
RBC Lowers Price Target on Viridian Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - MarketScreener
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Viridian Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments - TipRanks
Viridian (VRDN) Reports Q2 Revenue Surpassing Estimates, Cash Position Supports Operations into 2027. - AInvest
Viridian Therapeutics Grants Inducement Stock Options to New Employees - AInvest
Viridian Therapeutics: Hold Rating and Awaited 2026 Developments - AInvest
Viridian 2025 Q2 Earnings Wider Losses Amid Regulatory and Partnership Momentum - AInvest
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating - TipRanks
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments - TipRanks
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements - TipRanks
Viridian (VRDN) Q2 Net Loss Widens 55% - AOL.com
Viridian Therapeutics Q2 Net Loss Widens, Revenue Increases - MarketScreener
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Rises With Strong Cash And Clinical Progress - Finimize
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Viridian Therapeutics Q2 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $75,000, vs. FactSet Est of $100,000 - MarketScreener
Earnings Flash (VRDN) Viridian Therapeutics Posts Q2 Net Loss $1.00 a Share, vs. FactSet Est of $1.00 Loss - MarketScreener
Viridian Therapeutics shares rise 3.86% intraday after announcing inducement grants to new employees. - AInvest
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
What makes Viridian Therapeutics Inc. stock price move sharplyGet expert insights on market-moving stocks - Jammu Links News
When is Viridian Therapeutics Inc. stock expected to show significant growthStrong return on assets - Jammu Links News
What are the latest earnings results for Viridian Therapeutics Inc.Breakout portfolio performance - Jammu Links News
What is Viridian Therapeutics Inc. company’s growth strategyUnlock daily market insights for better trades - Jammu Links News
Is Viridian Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is it the right time to buy Viridian Therapeutics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
What analysts say about Viridian Therapeutics Inc. stockExplosive trading growth - Jammu Links News
How does Viridian Therapeutics Inc. compare to its industry peersMarket-leading capital gains - Jammu Links News
Why is Viridian Therapeutics Inc. stock attracting strong analyst attentionGet expert insights on market-moving stocks - Jammu Links News
What is the dividend policy of Viridian Therapeutics Inc. stockUnprecedented profit potential - Jammu Links News
How strong is Viridian Therapeutics Inc. company’s balance sheetGet timely market insights for better trades - jammulinksnews.com
What catalysts could drive Viridian Therapeutics Inc. stock higher in 2025Unprecedented market success - Jammu Links News
What institutional investors are buying Viridian Therapeutics Inc. stockAchieve superior returns through strategic trading - Jammu Links News
Viridian Therapeutics Collaborates with Kissei Pharmaceutical for Veligrotug and VRDN-003 Development in Japan - AInvest
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan - Yahoo Finance
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):